Absolute coronary flow and microvascular resistance before and after transcatheter aortic valve implantation.


Journal

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
ISSN: 1969-6213
Titre abrégé: EuroIntervention
Pays: France
ID NLM: 101251040

Informations de publication

Date de publication:
07 Oct 2024
Historique:
medline: 7 10 2024
pubmed: 7 10 2024
entrez: 7 10 2024
Statut: epublish

Résumé

Severe aortic stenosis (AS) is associated with left ventricular (LV) remodelling, likely causing alterations in coronary blood flow and microvascular resistance. We aimed to evaluate changes in absolute coronary flow and microvascular resistance in patients with AS undergoing transcatheter aortic valve implantation (TAVI). Consecutive patients with AS undergoing TAVI with non-obstructive coronary artery disease in the left anterior descending artery (LAD) were included. Absolute coronary flow (Q) and microvascular resistance (R In 51 patients, Q and R were measured at rest and during hyperaemia before and after TAVI; in 20 (39%) patients, measurements were also obtained 6 months after TAVI. No changes occurred in resting and hyperaemic flow and resistance before and after TAVI nor after 6 months. However, at 6-month follow-up, a notable reverse LV remodelling resulted in a significant increase in hyperaemic perfusion (Q Immediately after TAVI, no changes occurred in absolute coronary flow or coronary flow reserve. Over time, the remodelling of the left ventricle is associated with increased hyperaemic perfusion.

Sections du résumé

BACKGROUND BACKGROUND
Severe aortic stenosis (AS) is associated with left ventricular (LV) remodelling, likely causing alterations in coronary blood flow and microvascular resistance.
AIMS OBJECTIVE
We aimed to evaluate changes in absolute coronary flow and microvascular resistance in patients with AS undergoing transcatheter aortic valve implantation (TAVI).
METHODS METHODS
Consecutive patients with AS undergoing TAVI with non-obstructive coronary artery disease in the left anterior descending artery (LAD) were included. Absolute coronary flow (Q) and microvascular resistance (R
RESULTS RESULTS
In 51 patients, Q and R were measured at rest and during hyperaemia before and after TAVI; in 20 (39%) patients, measurements were also obtained 6 months after TAVI. No changes occurred in resting and hyperaemic flow and resistance before and after TAVI nor after 6 months. However, at 6-month follow-up, a notable reverse LV remodelling resulted in a significant increase in hyperaemic perfusion (Q
CONCLUSIONS CONCLUSIONS
Immediately after TAVI, no changes occurred in absolute coronary flow or coronary flow reserve. Over time, the remodelling of the left ventricle is associated with increased hyperaemic perfusion.

Identifiants

pubmed: 39374094
pii: EIJ-D-24-00075
doi: 10.4244/EIJ-D-24-00075
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1248-e1528

Auteurs

Emanuele Gallinoro (E)

Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.
Division of University Cardiology, IRCCS Galeazzi - Sant'Ambrogio Hospital, Milan, Italy.

Pasquale Paolisso (P)

Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.
Division of University Cardiology, IRCCS Galeazzi - Sant'Ambrogio Hospital, Milan, Italy.

Dario Tino Bertolone (DT)

Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.

Giuseppe Esposito (G)

Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.
Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.

Marta Belmonte (M)

Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.
Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.

Attilio Leone (A)

Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.
Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.

Michele Mattia Viscusi (MM)

Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.
Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.

Monika Shumkova (M)

Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.

Cristina De Colle (C)

Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.

Ivan Degrieck (I)

Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.

Filip Casselman (F)

Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.

Martin Penicka (M)

Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.

Carlos Collet (C)

Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.

Jeroen Sonck (J)

Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.

Eric Wyffels (E)

Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.

Jozef Bartunek (J)

Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.

Bernard De Bruyne (B)

Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.
Department of Cardiology, Lausanne University Hospital, Lausanne, Switzerland.

Marc Vanderheyden (M)

Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.

Emanuele Barbato (E)

Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.
Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH